Suppr超能文献

甲状旁腺同种异体移植:系统评价。

Parathyroid Allotransplantation: A Systematic Review.

机构信息

Department of Surgery, Leiden University Medical Center, 2333 Leiden, The Netherlands.

Department of Internal Medicine, Division Endocrinology, Leiden University Medical Center, 2333 Leiden, The Netherlands.

出版信息

Med Sci (Basel). 2022 Mar 15;10(1):19. doi: 10.3390/medsci10010019.

Abstract

: To date, there is no satisfactory treatment for patients with calcium and vitamin D supplementation refractive hypoparathyroidism. Parathyroid allotransplantation by design is a one-time cure through its restoration of the parathyroid function and, therefore, could be the solution. A systematic literature review is conducted in the present paper, with the aim of outlining the possibilities of parathyroid allotransplantation and to calculate its efficacy. Additionally, various transplantation characteristics are linked to success. This review is carried out according to the PRISMA statement and checklist. Relevant articles were searched for in medical databases with the most recent literature search performed on 9 December 2021. In total, 24 articles involving 22 unique patient cohorts were identified with 203 transplantations performed on 148 patients. Numerous types of (exploratory) interventions were carried out with virtually no protocols that were alike: there was the use of (non-) cryopreserved parathyroid tissue combined with direct transplantation or pretreatment using in vitro techniques, such as culturing cells and macro-/microencapsulation. The variability increased further when considering immunosuppression, graft histology, and donor-recipient compatibility, but this was found to be reported in its entirety by exception. As a result of the large heterogeneity among studies, we constructed our own criterium for transplantation success. With only the studies eligible for our assessment, the pooled success rate for parathyroid allotransplantation emerged to be 46% (13/28 transplantations) with a median follow-up duration of 12 months (Q1-Q3: 8-24 months). Manifold possibilities have been explored around parathyroid allotransplantation but are presented as a double-edged sword due to high clinical diverseness, low expertise in carrying out the procedure, and unsatisfactory study quality. Transplantations carried out with permanent immunosuppression seem to be the most promising, but, in its current state, little could be said about the treatment efficacy with a high quality of evidence. Of foremost importance in pursuing the answer whether parathyroid allotransplantation is a suitable treatment for hypoparathyroidism, a standardized definition of transplantation success must be established with a high-quality trial.

摘要

到目前为止,对于接受钙和维生素 D 补充的反射性甲状旁腺功能减退症患者,尚无令人满意的治疗方法。甲状旁腺同种异体移植通过设计一次治愈,恢复甲状旁腺功能,因此可以成为解决方案。本文进行了系统的文献回顾,旨在概述甲状旁腺同种异体移植的可能性并计算其疗效。此外,各种移植特征与成功相关。

本综述根据 PRISMA 声明和清单进行。在医学数据库中搜索相关文章,并于 2021 年 12 月 9 日进行了最新的文献检索。总共确定了 24 篇文章,涉及 22 个独特的患者队列,对 148 名患者进行了 203 次移植。进行了许多类型的(探索性)干预,但几乎没有相同的方案:使用(非)冷冻保存的甲状旁腺组织与直接移植或使用体外技术(如细胞培养和宏观/微囊化)预处理相结合。当考虑免疫抑制、移植物组织学和供体-受者相容性时,变异性进一步增加,但通过例外情况发现了全部报告。由于研究之间存在很大的异质性,我们为移植成功制定了自己的标准。只有符合我们评估标准的研究,甲状旁腺同种异体移植的总成功率为 46%(28 次移植中的 13 次),中位随访时间为 12 个月(Q1-Q3:8-24 个月)。

甲状旁腺同种异体移植已经探索了多种可能性,但由于临床多样性高、执行该程序的专业知识有限以及研究质量不高,因此被视为双刃剑。永久性免疫抑制的移植似乎最有前途,但就目前而言,由于证据质量低,关于治疗效果的信息很少。在探讨甲状旁腺同种异体移植是否适合治疗甲状旁腺功能减退症时,最重要的是建立一个标准化的移植成功定义,并进行高质量的试验。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db98/8953572/811bda28989d/medsci-10-00019-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验